{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:08:30Z","timestamp":1791418110073,"version":"4.3.3"},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The phase III AUGMENT trial (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01938001\">NCT01938001<\/jats:ext-link>\n                      ) demonstrated improved efficacy for lenalidomide plus rituximab (R\n                      <jats:sup>2<\/jats:sup>\n                      ) versus rituximab with placebo (R-placebo) in patients with relapsed or refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Here, we present the long-term follow-up results and prespecified subgroup analyses of patients with follicular lymphoma (FL), including those 70 years and older. Patients with R\/R grade 1 to 3a iNHL were randomly assigned 1:1 to receive R\n                      <jats:sup>2<\/jats:sup>\n                      or R-placebo. In this long-term follow-up report, progression-free survival (PFS) was assessed per the investigator. Secondary end points included overall survival (OS) and safety. Of the 358 randomly assigned patients (intent-to-treat [ITT] population), 295 had FL (\u226570 years, n = 66). At long-term follow-up (median, 65.9 months), in the ITT iNHL population, PFS (hazard ratio [HR], 0.50 [95% CI, 0.38 to 0.66]) and OS (HR, 0.59 [95% CI, 0.37 to 0.95]) were improved with R\n                      <jats:sup>2<\/jats:sup>\n                      versus R-placebo. Safety findings were consistent with the primary analysis. Improved long-term efficacy with R\n                      <jats:sup>2<\/jats:sup>\n                      versus R-placebo and manageable safety with R\n                      <jats:sup>2<\/jats:sup>\n                      were observed in patients with FL, including those 70 years and older. With a follow-up of &gt;5 years, data from the AUGMENT trial continue to support the use of R\n                      <jats:sup>2<\/jats:sup>\n                      as a standard of care for patients with R\/R iNHL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-01770","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:59:20Z","timestamp":1776369560000},"page":"1483-1489","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Lenalidomide Plus Rituximab for Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct01938001","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-1115","authenticated-orcid":true,"given":"John P.","family":"Leonard","sequence":"first","affiliation":[{"name":"Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":true,"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"Charles University, General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":true,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":true,"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":true,"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Hopital Saint-Louis, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":true,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, Bologna, Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Gkasiamis","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ryun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-7430","authenticated-orcid":true,"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AUGMENT Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_11_5_2","first-page":"5","article-title":"Epidemiology of Non-Hodgkin's lymphoma","volume":"9","author":"Thandra KC","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, et al: Epidemiology of Non-Hodgkin's lymphoma. Med Sci (Basel) 9:5, 2021","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_11_6_2","first-page":"34","article-title":"Lymphoma: Diagnosis and treatment","volume":"101","author":"Lewis WD","year":"2020","unstructured":"Lewis WD, Lilly S, Jones KL: Lymphoma: Diagnosis and treatment. Am Fam Physician 101:34-41, 2020","journal-title":"Am Fam Physician"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds643"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds517"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S267258"},{"key":"e_1_3_11_10_2","volume-title":"Rituxan (Rituximab) Prescribing Information","author":"Genentech","year":"2021","unstructured":"Genentech: Rituxan (Rituximab) Prescribing Information. 2021. https:\/\/www.rituxan-hcp.com\/ra.html?c=rti-17546b9f6a8&gclid=30087f3d596e1d0689c81a4d2b438462&gclsrc=3p.ds&"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"e_1_3_11_13_2","unstructured":"European Medicines Agency. MabThera (rituximab) \u2013 An overview of MabThera and why it is authorised in the EU. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mabthera-epar-medicine-overview_en.pdf"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"e_1_3_11_19_2","volume-title":"Revlimid (Lenalidomide) Medication Guide","author":"Bristol Myers Squibb","year":"2023","unstructured":"Bristol Myers Squibb: Revlimid (Lenalidomide) Medication Guide. 2023. https:\/\/packageinserts.bms.com\/medguide\/medguide_revlimid.pdf"},{"key":"e_1_3_11_20_2","volume-title":"Revlimid (Lenalidomide) Summary of Product Characteristics","author":"Bristol Myers Squibb","year":"2017","unstructured":"Bristol Myers Squibb: Revlimid (Lenalidomide) Summary of Product Characteristics. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revlimid-epar-product-information_en.pdf"},{"key":"e_1_3_11_21_2","volume-title":"Revlimid (Lenalidomide) Product Information","author":"Bristol Myers Squibb","year":"2021","unstructured":"Bristol Myers Squibb: Revlimid (Lenalidomide) Product Information. Brazil, 2021. https:\/\/www.bms.com\/assets\/bms\/brazil\/documents\/REVLIMID_CAPS_VP_v05_19042019.pdf"},{"key":"e_1_3_11_22_2","unstructured":"National Cancer Institute: SEER stat fact sheets: Follicular lymphoma. 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html"}],"updated-by":[{"DOI":"10.1200\/jco-26-01085","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:59:27Z","timestamp":1779919167000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1200\/JCO-25-01770"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01770","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2025-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}